AstraZeneca : positive review from FDA

The FDA granted Farxiga in the US.

Downtrend 4

AstraZeneca, a global biopharmaceutical company, announced that its Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for patients with chronic kidney disease.

From a chartist point of view, on a daily chart, prices are stuck below the resistance at 8848. The 50 day MA is negatively oriented above prices while the RSI is in bearish territory. As long as the 8848 resistance is not broken, readers may therefore consider further downside towards 7930 and 7121 in extension.

Source : TradingVIEW, Gain Capital

More from Equities

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.